11/26
07:15 am
arvn
Arvinas to Present at Piper Sandler 37th Annual Healthcare Conference [Yahoo! Finance]
Low
Report
Arvinas to Present at Piper Sandler 37th Annual Healthcare Conference [Yahoo! Finance]
11/26
07:00 am
arvn
Arvinas to Present at Piper Sandler 37th Annual Healthcare Conference
Low
Report
Arvinas to Present at Piper Sandler 37th Annual Healthcare Conference
11/24
07:00 am
arvn
Arvinas Announces Data Presentations from the Vepdegestrant (ARV-471) Clinical Development Program at the 2025 San Antonio Breast Cancer Symposium (SABCS)
Low
Report
Arvinas Announces Data Presentations from the Vepdegestrant (ARV-471) Clinical Development Program at the 2025 San Antonio Breast Cancer Symposium (SABCS)
11/18
12:30 am
arvn
Revisiting the Narrative for Arvinas as Analyst Views Shift with New Pipeline and Partner Risks [Yahoo! Finance]
High
Report
Revisiting the Narrative for Arvinas as Analyst Views Shift with New Pipeline and Partner Risks [Yahoo! Finance]
11/10
09:25 am
arvn
Arvinas (NASDAQ:ARVN) had its price target raised by analysts at Stephens from $14.00 to $15.00. They now have an "overweight" rating on the stock.
Medium
Report
Arvinas (NASDAQ:ARVN) had its price target raised by analysts at Stephens from $14.00 to $15.00. They now have an "overweight" rating on the stock.
11/6
01:21 pm
arvn
Arvinas (NASDAQ:ARVN) had its "neutral" rating reaffirmed by analysts at Wedbush. They now have a $9.00 price target on the stock.
Low
Report
Arvinas (NASDAQ:ARVN) had its "neutral" rating reaffirmed by analysts at Wedbush. They now have a $9.00 price target on the stock.
11/6
10:50 am
arvn
Arvinas (NASDAQ:ARVN) had its price target lowered by analysts at Wells Fargo & Company from $16.00 to $15.00. They now have an "overweight" rating on the stock.
Low
Report
Arvinas (NASDAQ:ARVN) had its price target lowered by analysts at Wells Fargo & Company from $16.00 to $15.00. They now have an "overweight" rating on the stock.
11/6
09:35 am
arvn
Arvinas (NASDAQ:ARVN) had its price target raised by analysts at Barclays PLC from $15.00 to $16.00. They now have an "overweight" rating on the stock.
Low
Report
Arvinas (NASDAQ:ARVN) had its price target raised by analysts at Barclays PLC from $15.00 to $16.00. They now have an "overweight" rating on the stock.
11/5
10:46 pm
arvn
Arvinas (ARVN): Losses Accelerate 7.7% Annually, but Stock Trades at Peer-Low 1.9x Sales [Yahoo! Finance]
Medium
Report
Arvinas (ARVN): Losses Accelerate 7.7% Annually, but Stock Trades at Peer-Low 1.9x Sales [Yahoo! Finance]
11/5
07:00 am
arvn
Arvinas Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Low
Report
Arvinas Reports Third Quarter 2025 Financial Results and Provides Corporate Update
11/3
04:00 pm
arvn
Arvinas to Present Preclinical Data for ARV-393 at the 2025 American Society of Hematology (ASH) Annual Meeting
Low
Report
Arvinas to Present Preclinical Data for ARV-393 at the 2025 American Society of Hematology (ASH) Annual Meeting
11/3
07:00 am
arvn
Arvinas to Participate in Upcoming Investor Conferences
Low
Report
Arvinas to Participate in Upcoming Investor Conferences
10/30
08:07 am
arvn
Arvinas (NASDAQ:ARVN) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $14.00 price target on the stock, up previously from $10.00.
Low
Report
Arvinas (NASDAQ:ARVN) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $14.00 price target on the stock, up previously from $10.00.
10/29
07:00 am
arvn
Arvinas to Report Third Quarter 2025 Financial Results on November 5, 2025
Low
Report
Arvinas to Report Third Quarter 2025 Financial Results on November 5, 2025
10/24
04:21 pm
arvn
Arvinas Presents Preclinical Data for ARV-806 Demonstrating Robust and Differentiated Activity in Models of KRAS G12D-mutated Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics [Yahoo! Finance]
Low
Report
Arvinas Presents Preclinical Data for ARV-806 Demonstrating Robust and Differentiated Activity in Models of KRAS G12D-mutated Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics [Yahoo! Finance]
10/24
04:00 pm
arvn
Arvinas Presents Preclinical Data for ARV-806 Demonstrating Robust and Differentiated Activity in Models of KRAS G12D-mutated Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Medium
Report
Arvinas Presents Preclinical Data for ARV-806 Demonstrating Robust and Differentiated Activity in Models of KRAS G12D-mutated Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
10/22
04:09 pm
arvn
Arvinas to Present Preclinical Data for ARV-806, a PROTAC KRAS G12D Degrader, at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics [Yahoo! Finance]
Low
Report
Arvinas to Present Preclinical Data for ARV-806, a PROTAC KRAS G12D Degrader, at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics [Yahoo! Finance]
10/22
04:00 pm
arvn
Arvinas to Present Preclinical Data for ARV-806, a PROTAC KRAS G12D Degrader, at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Low
Report
Arvinas to Present Preclinical Data for ARV-806, a PROTAC KRAS G12D Degrader, at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
10/20
04:15 am
arvn
Patient-Reported Outcomes from VERITAC-2 Clinical Trial Support Clinical Benefit of Vepdegestrant in Patients with ESR1-Mutated, ER+/HER2- Advanced or Metastatic Breast Cancer Previously Treated with Endocrine-Based Therapy
Low
Report
Patient-Reported Outcomes from VERITAC-2 Clinical Trial Support Clinical Benefit of Vepdegestrant in Patients with ESR1-Mutated, ER+/HER2- Advanced or Metastatic Breast Cancer Previously Treated with Endocrine-Based Therapy
10/15
06:01 am
arvn
Arvinas (NASDAQ:ARVN) was given a new $6.00 price target on by analysts at The Goldman Sachs Group, Inc..
Medium
Report
Arvinas (NASDAQ:ARVN) was given a new $6.00 price target on by analysts at The Goldman Sachs Group, Inc..
10/13
07:11 am
arvn
Arvinas to Present Data from the Vepdegestrant Clinical Development Program at the 2025 European Society for Medical Oncology (ESMO) Congress [Yahoo! Finance]
Medium
Report
Arvinas to Present Data from the Vepdegestrant Clinical Development Program at the 2025 European Society for Medical Oncology (ESMO) Congress [Yahoo! Finance]
10/13
07:00 am
arvn
Arvinas to Present Data from the Vepdegestrant Clinical Development Program at the 2025 European Society for Medical Oncology (ESMO) Congress
Medium
Report
Arvinas to Present Data from the Vepdegestrant Clinical Development Program at the 2025 European Society for Medical Oncology (ESMO) Congress
10/7
01:02 pm
arvn
Arvinas (NASDAQ:ARVN) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
Low
Report
Arvinas (NASDAQ:ARVN) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
10/5
02:00 pm
arvn
Arvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson’s Disease and Movement Disorders®
Low
Report
Arvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson’s Disease and Movement Disorders®
10/3
03:30 pm
arvn
Arvinas (NASDAQ:ARVN) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Arvinas (NASDAQ:ARVN) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.